Sandoz opens high-volume biosimilar drug substance manufacturing center in Lendava, Slovenia

By Public Technologies
  • Sandoz Group AG opened a high-volume biosimilar drug-substance manufacturing center in Lendava, Slovenia, expanding in-house production capacity.
  • Facility strengthens supply flexibility across Sandoz’s European biosimilar network, supporting its Bio100 target of more than 100 biosimilars by 2040.
  • Site uses automation and process analytical technology from development through full-scale manufacturing, built to international safety, quality, environmental standards.
  • Expansion adds more than 300 staff, complementing continuous manufacturing in Toulouse and planned disposable fed-batch investment in Ljubljana.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2406294_en) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk